Details of the Drug-Related molecule(s) Interaction Atlas

HELENALIN Drug Info

HELENALIN; 6754-13-8; PF 56; Helenalin A; HSDB 3490; NSC85236; UNII-4GUY9L896T; NSC 85236; BRN 0028081; MLS000728512; CHEBI:5635; 4GUY9L896T; 6alpha,8beta-Dihydroxy-4-oxoambrosa-2,11(13)-dien-12-oic acid 12,8-lactone; SMR000445626; Ambrosa-2,11(13)-dien-12-oic acid, 6alpha,8beta-dihydroxy-4-oxo-, 12,8-lactone; (3aR,5R,5aR,8aR,9S,9aS)-9-hydroxy-5,8a-dimethyl-1-methylene-3a,4,5,5a,9,9a-hexahydroazuleno[6,7-b]furan-2,8-dione; Azuleno(6,5-b)furan-2,5-dione, 3,3a,4,4a,7a,8,9,9a-octahydro-4-hydroxy-4a,8-dimethyl-3-methylene-, (3

Cross-matching ID

PubChem CID

23205

ChEBI ID

CHEBI:5635

CAS Number

CAS 6754-13-8

TTD Drug ID

DMMCI4H

General Information of Drug (ID: DMMCI4H)

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Angiotensin II receptor type-1 (AGTR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Losartan	DM72JXH	Diabetic kidney disease	GB61.Z	Approved	[6]
Olmesartan medoxomil	DMWBHRY	High blood pressure	BA00	Approved	[7]
Irbesartan	DMTP1DC	Diabetic kidney disease	GB61.Z	Approved	[6]
Valsartan	DMREUQ6	Chronic heart failure	BD1Z	Approved	[6]
Candesartan	DMRK8OT	Chronic heart failure	BD1Z	Approved	[8]
Telmisartan	DMS3GX2	Hypertension	BA00-BA04	Approved	[9]
ANGIOTENSIN II	DMLWQ27	Increase blood pressure	BA04	Approved	[10]
SARALASIN	DMKS1DV	Hypertension	BA00-BA04	Approved	[11]
Tasosartan	DMM13DI	Hypertension	BA00-BA04	Approved	[12]
Eprosartan	DM07K2I	Hypertension	BA00-BA04	Approved	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Nuclear factor NF-kappa-B (NFKB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[14]
Triptolide	DMCMDVR	Autoimmune diabetes	5A10	Phase 3	[15]
Laquinimod	DM3IWS8	Lupus	4A40	Phase 3	[16]
Edasalonexent	DMYVBF6	Duchenne dystrophy	8C70	Phase 3	[17]
MD1003	DMVZ57G	Multiple sclerosis	8A40	Phase 3	[17]
Vadimezan	DMK7CYX	Solid tumour/cancer	2A00-2F9Z	Phase 2	[18]
CAT 1004	DMQBP7R	Duchenne dystrophy	8C70	Phase 2	[19]
Parthenolide	DMCQBFT	N. A.	N. A.	Phase 2	[20]
Recoflavone	DMCSR8I	Inflammatory bowel disease	DD72	Phase 2	[21]
CZEN-002	DMUDMHA	Fungal infection	1F29-1F2F	Phase 2	[22]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cyclic AMP-dependent transcription factor ATF-4 (ATF4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[23]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[24]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[25]
Selenium	DM25CGV	N. A.	N. A.	Approved	[26]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[27]
Pyrazinamide	DM4IF32	Meningeal tuberculosis		Approved	[28]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[29]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[30]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[31]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[32]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By DNA damage-inducible transcript 3 protein (DDIT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[33]
Triacetin	DM0AEPG	Onychomycosis	EE12.1	Approved	[34]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[23]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[24]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[35]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[36]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[37]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[38]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[39]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Transcription factor p65 (RELA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[41]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[42]
Selenium	DM25CGV	N. A.	N. A.	Approved	[26]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[43]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[44]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[45]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[46]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[47]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[48]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By DNA damage-inducible transcript 4 protein (DDIT4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[33]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[49]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[50]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[51]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[52]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[53]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[54]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[55]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[56]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[57]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[58]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[59]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[60]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[61]
Clopidogrel	DMOL54H	Acute coronary syndrome	BA41	Approved	[62]
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[63]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[64]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[65]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[66]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[67]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[68]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[69]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[70]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[71]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[71]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[72]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[73]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[74]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[75]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[67]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[68]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[73]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[73]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[76]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[77]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[81]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[82]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[77]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[83]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[84]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[85]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[86]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[87]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[88]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[89]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 2A13 (CYP2A13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[90]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[91]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[91]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[92]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[93]
Acenaphthenol	DMT3QYZ	N. A.	N. A.	Investigative	[94]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[95]
BRN-3548355	DM4KXT0	N. A.	N. A.	Investigative	[95]
Chrysin	DM7V2LG	Discovery agent	N.A.	Investigative	[96]
9-phenanthrol	DMJFBQ1	Discovery agent	N.A.	Investigative	[97]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiotensin II receptor type-1 (AGTR1)	TT8DBY3	AGTR1_HUMAN	Inhibitor	[1]
Nuclear factor NF-kappa-B (NFKB)	TTSXVID	NFKB1_HUMAN; NFKB2_HUMAN; TF65_HUMAN; RELB_HUMAN; REL_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cyclic AMP-dependent transcription factor ATF-4 (ATF4)	OTRFV19J	ATF4_HUMAN	Gene/Protein Processing	[3]
Cytochrome P450 2A13 (CYP2A13)	OTVUDLT3	CP2AD_HUMAN	Biotransformations	[4]
Cytochrome P450 2B6 (CYP2B6)	OTOYO4S7	CP2B6_HUMAN	Biotransformations	[4]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Biotransformations	[4]
Cytochrome P450 3A5 (CYP3A5)	OTSXFBXB	CP3A5_HUMAN	Biotransformations	[4]
Cytochrome P450 3A7 (CYP3A7)	OTTCDHHM	CP3A7_HUMAN	Biotransformations	[4]
DNA damage-inducible transcript 3 protein (DDIT3)	OTI8YKKE	DDIT3_HUMAN	Gene/Protein Processing	[3]
DNA damage-inducible transcript 4 protein (DDIT4)	OTHY8SY4	DDIT4_HUMAN	Gene/Protein Processing	[3]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Gene/Protein Processing	[5]

------------------------------------------------------------------------------------

References

1	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
2	Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54.
3	Helenalin-induced apoptosis is dependent on production of reactive oxygen species and independent of induction of endoplasmic reticulum stress in renal cell carcinoma. Toxicol In Vitro. 2013 Mar;27(2):588-96. doi: 10.1016/j.tiv.2012.10.014. Epub 2012 Oct 30.
4	In vitro metabolism of helenalin and its inhibitory effect on human cytochrome P450 activity. Arch Toxicol. 2022 Mar;96(3):793-808. doi: 10.1007/s00204-021-03218-6. Epub 2022 Jan 6.
5	Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-kappaB activation. Cancer Res. 2005 Jun 1;65(11):4909-17. doi: 10.1158/0008-5472.CAN-04-4124.
6	Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
7	Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol. 2009 Jul;54(1):47-56.
8	Candesartan: widening indications for this angiotensin II receptor blocker Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007.
9	Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35.
10	The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
11	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
12	Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54.
13	Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7.
14	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
15	Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001 Nov 29;20(55):8009-18.
16	Reduced astrocytic NF- B activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124(3):411-24.
17	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
18	Auckland Cancer Society Research Centre report
19	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
20	Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med. 2005 Jan 3;201(1):105-15.
21	DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis. Exp Biol Med (Maywood). 2008 Feb;233(2):180-91.
22	US patent application no. US20100278784 A1.
23	Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
24	Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 2011 Mar;13(3):267-79. doi: 10.1093/neuonc/noq195. Epub 2011 Feb 3.
25	Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
26	Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
27	Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
28	Pyrazinamide-induced hepatotoxicity is alleviated by 4-PBA via inhibition of the PERK-eIF2-ATF4-CHOP pathway. Toxicology. 2017 Mar 1;378:65-75. doi: 10.1016/j.tox.2017.01.002. Epub 2017 Jan 4.
29	NGBR is required to ameliorate type 2 diabetes in mice by enhancing insulin sensitivity. J Biol Chem. 2021 Jan-Jun;296:100624. doi: 10.1016/j.jbc.2021.100624. Epub 2021 Apr 2.
30	Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
31	Rifampicin-induced injury in L02 cells is alleviated by 4-PBA via inhibition of the PERK-ATF4-CHOP pathway. Toxicol In Vitro. 2016 Oct;36:186-196. doi: 10.1016/j.tiv.2016.07.017. Epub 2016 Jul 26.
32	Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia. J Cell Mol Med. 2018 Mar;22(3):1614-1626.
33	Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
34	Induction of CCAAT/enhancer-binding protein-homologous protein by cigarette smoke through the superoxide anion-triggered PERK-eIF2 pathway. Toxicology. 2011 Sep 5;287(1-3):105-12. doi: 10.1016/j.tox.2011.06.005. Epub 2011 Jun 15.
35	Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
36	Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
37	High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities. Arch Toxicol. 2017 Mar;91(3):1367-1383. doi: 10.1007/s00204-016-1781-0. Epub 2016 Jun 29.
38	Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury. Toxicol Sci. 2014 Jan;137(1):234-48. doi: 10.1093/toxsci/kft232. Epub 2013 Oct 17.
39	Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
40	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
41	Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
42	-Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
43	Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
44	Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
45	Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
46	Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells. Immunology. 2007 May;121(1):71-81. doi: 10.1111/j.1365-2567.2006.02539.x.
47	Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
48	Glucosamine regulation of LPS-mediated inflammation in human bronchial epithelial cells. Eur J Pharmacol. 2010 Jun 10;635(1-3):219-26. doi: 10.1016/j.ejphar.2010.02.044. Epub 2010 Mar 20.
49	MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
50	Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
51	Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
52	Identification of troglitazone responsive genes: induction of RTP801 during troglitazone-induced apoptosis in Hep 3B cells. BMB Rep. 2010 Sep;43(9):599-603. doi: 10.5483/BMBRep.2010.43.9.599.
53	Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
54	Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
55	Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
56	In vitro effects of aldehydes present in tobacco smoke on gene expression in human lung alveolar epithelial cells. Toxicol In Vitro. 2013 Apr;27(3):1072-81.
57	Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
58	Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
59	Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
60	Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor. Chem Res Toxicol. 2014 Feb 17;27(2):304-308.
61	Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem. 2004 Jul 9;279(28):29295-301. doi: 10.1074/jbc.M400580200. Epub 2004 Apr 28.
62	Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
63	Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
64	Characterization of human cytochrome P450 induction by pesticides. Toxicology. 2012 Mar 29;294(1):17-26.
65	Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
66	Pyrethroids: cytotoxicity and induction of CYP isoforms in human hepatocytes. Drug Metabol Drug Interact. 2008;23(3-4):211-36.
67	The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
68	Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
69	Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
70	The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
71	Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
72	Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
73	Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
74	Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
75	Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
76	Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos. 2005 Jul;33(7):1074-81. doi: 10.1124/dmd.104.002279. Epub 2005 Apr 8.
77	Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
78	Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. J Toxicol Sci. 2017;42(3):343-348.
79	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
80	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
81	Induction of hepatic CYP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines. Drug Metab Dispos. 2013 Feb;41(2):281-90.
82	Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
83	Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
84	Human drug metabolism genes in parathion-and estrogen-treated breast cells. Int J Mol Med. 2007 Dec;20(6):875-81.
85	Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol. 2009 Feb 1;234(3):345-60.
86	Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.
87	Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther. 2005 Aug;314(2):626-35. doi: 10.1124/jpet.105.086504. Epub 2005 Apr 21.
88	Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol. 2010 Nov;161(5):1059-69. doi: 10.1111/j.1476-5381.2010.00946.x.
89	Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
90	CYP1A1/1B1 and CYP2A6/2A13 activity is conserved in cultures of differentiated primary human tracheobronchial epithelial cells. Toxicol In Vitro. 2011 Jun;25(4):922-9.
91	Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
92	Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
93	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
94	Oxidation of Acenaphthene and Acenaphthylene by Human Cytochrome P450 Enzymes. Chem Res Toxicol. 2015 Feb 16;28(2):268-78.
95	Functional characterization of CYP2A13 polymorphisms. Xenobiotica. 2007 Dec;37(12):1439-49. doi: 10.1080/00498250701666265.
96	Oxidation of Flavone, 5-Hydroxyflavone, and 5,7-Dihydroxyflavone to Mono-, Di-, and Tri-Hydroxyflavones by Human Cytochrome P450 Enzymes. Chem Res Toxicol. 2019 Jun 17;32(6):1268-1280. doi: 10.1021/acs.chemrestox.9b00078. Epub 2019 Apr 17.
97	Structure-Function Studies of Naphthalene, Phenanthrene, Biphenyl, and Their Derivatives in Interaction with and Oxidation by Cytochromes P450 2A13 and 2A6. Chem Res Toxicol. 2016 Jun 20;29(6):1029-40. doi: 10.1021/acs.chemrestox.6b00083. Epub 2016 May 12.